You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

333 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
tamoxifen
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab (Unfunded),
CISplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab (Unfunded),
CARBOplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (Unfunded),
bortezomib (Unfunded),
lenalidomide (Unfunded),
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
pomalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
atezolizumab (subcut),
CARBOplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
atezolizumab (subcut),
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    relugolix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
relugolix
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Drug
Other Name(s): Orgovyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (subcut) (Unfunded),
bortezomib (Unfunded),
lenalidomide (Unfunded),
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brentuximab vedotin (Unfunded),
DOXOrubicin,
cyclophosphamide,
etoposide,
dacarbazine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025

Pages